REGULATORY

GSK’s Cost-Effectiveness Analysis for Trelegy Delayed, First Product under Full CEA Scheme

May 28, 2020

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Last May, GlaxoSmithKline’s COPD therapy Trelegy (fluticasone furoate + umeclidinium + vilanterol) became the first drug selected for Japan’s full-scale cost-effectiveness assessment (CEA) scheme. A year later, regulators revealed that GSK’s CEA was delayed by two months, with the company…

To read the full story

MHLW Unveils Outline of Cost-Effective Assessment Scheme: Chuikyo
January 24, 2019

REGULATORY

Govt’s Honebuto Draft Confirms FY2027 Off-Year Drug Price Revision
July 1, 2026
Govt Presents Growth Strategy Draft Ahead of July Approval
July 1, 2026
Lower House Clears Immunization Act Revision
July 1, 2026
LDP Cautious over Ishin’s GDP-Linked Healthcare Spending Proposal
July 1, 2026
Japan Begins Review of Domestic CGT Seeds with Limited Market Potential
June 30, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COLUMN

The Psychology of ‘Stuck’: Understanding Why Changing Jobs Feels So Hard

By Philip Carrigan

Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…